Oxiconazole|CAS 64211-46-7|DC Chemicals

Cas No.:	64211-46-7
Chemical Name:	(Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine;nitric acid
Synonyms:	Oxiconazole, Oxistat, Oxizole, Fonx, Myfungar; Ro 13-8996; Ro-13-8996; Ro13-8996; Sgd 301-76; ST 813; ST-813; ST813;
SMILES:	C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl.[N+](=O)(O)[O-]
Formula:	C₁₈H₁₄Cl₄N₄O₄
M.Wt:	492.1402
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Oxiconazole nitrate is a broad spectrum antifungal which can inhibit the growth of T. tonsurans and T. rubrum with MIC90s of 0.25 and 0.5 μg/mL, respectively.
Target:	MIC90: 0.25 μg/mL (T. tonsurans), 0.5 μg/mL (T. rubrum)[1]
In Vivo:	The baseline distortion product otoacoustic emission (DPOAE) results of the right ears of all animals tested are normal. Animals in groups I, II, IV and V show no statistically significant change in the DPOAE amplitudes. The rats in the gentamicingroup show a significant decrease[2].
In Vitro:	Oxiconazole nitrate is the more active compound in tests with T. tonsurans and T. rubrum. Twelve isolates are inhibited by 0.063 μg/mL of oxiconazole; corresponding econazole MICs range from 0.063 (three isolates) to 8 (two isolates) μg/mL. Three isolates have oxiconazole MICs of 16 or 32 μg/mL[1].
Cell Assay:	A total of 121 isolates of pathogenic fungi are tested. The three drugs (including Oxiconazole nitrate) are serially diluted in sterile saline. For each test plate, 2 mL of a solution of drug in sterile saline is added to an 18 mL blank of molten agar medium at 50°C and mixed well; the resulting mixtures are then poured into the plates and allowed to solidify. The resulting drug dilution sequences range from 128 to 0.063 μg/mL. Control plates are prepared in a similar manner using 2 mL blanks of sterile saline. The plates are then inoculated using a replicator. Incubation is at 30°C for a minimum of 96 hr. The Minimal Inhibitory Concentration (MIC) is defined as the lowest concentration of drug producing complete inhibition of growth[1]
Animal Administration:	Fifty adult rats are divided into 5 groups consisting of 10 animals each. Over 14 days, the rats in group I receive 0.1 mL of Oxiconazole nitrate-containing solution drops, group II receives 4% boric acid solution in alcohol drops, and groups III and IV receive gentamicin (40 mg/mL) and saline solutions, respectively. Group V receives no medication. Each solution used is given twice a day[2].
References:	[1]. Shadomy S, et al. Further in vitro studies with oxiconazole nitrate. Diagn Microbiol Infect Dis. 1988 Apr;9(4):231-7. [2]. Özdemir S, et al. Effects of topical oxiconazole and boric acid in alcohol solutions to rat inner ears. Otolaryngol Head Neck Surg. 2013 Jun;148(6):1023-7.

Cat. No.	Product name	Field of application
DC31079	Abarelix	Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79856	EVT0185	EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
DC79609	NCGC00685960	NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC79112	Simepdekinra	Simepdekinra (Compound 221) is a IL-17A modulator with IC50s ≤10  nM and 10-100 nM for IL-17A/A HEK-Blue and IL-17A/F HEK-Blue cells. Simepdekinra can be used for inflammatory diseases such as psoriasis, ankylosing spondylitis and psoriatic arthritis research.
DC78751	RSL3-NH2	RSL3-NH2 is a GPX4 inhibitor and Ferroptosis inducer. RSL3-NH2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
DC77831	Vicadrostat	Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813	Zeltociclib	Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77784	UNC10013	UNC10013 is a SETDB1 allosteric modulator that forms a covalent bond with Cys385 in the 3TD domain, exhibiting negative allosteric regulatory activity. It has a kinact/KI value of 1.0 × 106 M-1*s-1. UNC10013 effectively disrupts SETDB1-mediated Akt methylation and holds potential value for research in cancer and neurodegenerative diseases.
DC77740	T0080	T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE−/− mice.